Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level

Masaaki Miyauchi; Masao Toyoda; Jie Zhang; Naoko Hamada; Takashi Yamawaki; Jun Tanaka; Kazuki Harada; Fumihiro Kashizaki; Masafumi Fukagawa

doi:10.1111/jdi.13143

Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level

J Diabetes Investig. 2020 May;11(3):748-749. doi: 10.1111/jdi.13143. Epub 2019 Oct 6.

Authors

Masaaki Miyauchi¹, Masao Toyoda², Jie Zhang³, Naoko Hamada³, Takashi Yamawaki³, Jun Tanaka⁴, Kazuki Harada⁴, Fumihiro Kashizaki⁴, Masafumi Fukagawa²

Affiliations

¹ Miyauchi Diabetes Clinic, Hadano, Japan.
² Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Kyodo Hospital, Isehara, Japan.
³ Division of Endocrinology and Diabetes, Department of Internal Medicine, Isehara Kyodo Hospital, Isehara, Japan.
⁴ Division of Respiratory Medicine, Department of Internal Medicine, Isehara Kyodo Hospital, Isehara, Japan.

Abstract

We describe here a case of nivolumab-induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects*
C-Peptide / blood*
Carcinoma, Non-Small-Cell Lung / drug therapy
Diabetes Mellitus, Type 1 / blood*
Diabetes Mellitus, Type 1 / chemically induced*
Humans
Immune Checkpoint Inhibitors / adverse effects*
Lung Neoplasms / drug therapy
Male
Nivolumab / adverse effects*

Substances

Antineoplastic Agents, Immunological
C-Peptide
Immune Checkpoint Inhibitors
Nivolumab